ClinicalTrials.gg
Active, not recruitingNCT04426786EBEPDUpdated Sep 2, 2026

Exercise & Brain Energetics in PD

An interventional study of Active exercise and Passive exercise in Parkinson Disease, sponsored by Pacific Parkinson's Research Centre. Active, not recruiting at 1 site in Canada. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Pacific Parkinson's Research Centre · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 253 studies in Parkinson Disease with a site in Canada — 43 open to participants now, 62 under way, 3 of them phase 3. Parkinson Disease · Canada.

Planned enrollment
127th of 212
40 · median 60
Started
2021
with 19 others
No phase
95 of 253
24 open now
Primary completion
2026-12
later than 32 of 61 live
Registered
175th of 253
by date
Lead sponsor
7 of 253
Pacific Parkinson's Research Centre

Among the 253 studies in Parkinson Disease with a site in Canada, this one is the 127th largest by planned enrollment of the 212 interventional ones that give a count, is one of 20 that started in 2021, is one of 95 with no phase, reaches primary completion later than 32 of the 61 other live ones, and was the 175th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

43 of the 253 studies in Parkinson Disease with a site in Canada are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies in Parkinson Disease with a site in Canada, or all of them as a file.
02

Study summary

There is increasing evidence that the usage and delivery of energy to the brain, known as brain energetics, is altered in people with Parkinson's disease (PD). This project will explore whether exercise has a positive impact on brain energetics using functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) brain scanning in PD subjects.

PD subjects will be scanned before and after a supervised exercise program to investigate the effect of exercise on brain energetics. In a separate study, the investigators will also scan healthy volunteers to compare brain energetics in the healthy brain with the brain energetics data in PD subjects acquired in this study.

Read the detailed description

Previous work has investigated the link between decreased brain energetics (through mitochondrial dysfunction), though an investigation in-vivo has never been feasible due to technology constraints. Furthermore, recent work has suggested exercise may help reduce the effect of mitochondrial dysfunction. There is thus compelling evidence to investigate brain energetics/mitochondrial function in-vivo, in health, at different stages of disease and the relationship to exercise. While such measurements are intrinsically difficult, a useful measure is expected to be derived from the ratio between the cerebral metabolic rate of oxygen (CMRO2) and the cerebral metabolic rate of glucose (CMRGlu), if they are measured simultaneously. The simultaneous aspect of the two measurements is extremely important as diurnal variations in CMRO2 can be as high as 20%, while those in CMRGlu as high as 38%. Fortunately, given recent advances in measurement technique and instrumentation development, such studies are now becoming possible: CMRO2 can be obtained using very advanced functional magnetic resonance imaging (fMRI) techniques with respiratory manipulations, while CMRGlu can be estimated by positron emission tomography (PET) using the tracer 18F-fluorodeoxyglucose (FDG-PET). A lower-than-normal ratio between CMRO2 and CMRGlu coupled with a decrease in CMRGlu in any brain area is taken to be indicative of locally impaired brain energetics, related to altered mitochondrial function.

The investigators hypothesize that (i) brain energetics, measured as the ratio CMRO2/CMRGlu is altered early in Parkinson's disease (PD) compared to age-matched healthy controls (HC) and continues to be altered as disease progresses; and (ii) exercise will positively affect alterations in brain energetics in PD subjects.

The investigators will recruit up to 30 PD subjects who are not habitual exercisers and up to 10 PD subjects who are habitual exercises. The 30 non-exercisers will undergo a supervised six month exercise intervention in groups, with PET/MRI scans before and after. The 10 exercisers will only be scanned once (for observational comparisons with the non-exercisers at baseline) and will not undergo the exercise intervention. In a separate study, the investigators will recruit up to 30 HCs to compare to compare their brain energetics metrics with those of the PD subjects at baseline to test hypothesis (i). Of the 30 non-exercisers, half will be assigned to start the exercise intervention immediately after their baseline scan, and the other half will have a six month delayed start to the intervention. During the delay, subjects will perform passive exercise in groups, to control for social interaction and possible placebo effects. Longitudinal comparisons of the non-exercisers before and after the intervention will test hypothesis (ii).

The objectives of this study are twofold: to (i) investigate a disease-initiating mechanism (abnormal mitochondrial function and impaired cellular bioenergetics), which could constitute a novel therapeutic target; and to (ii) study the effects of the intervention: while this will be a pilot study, involving limited exercise regimens, any knowledge gained about the impact of exercise on brain energetics will have a tremendous impact on the design of neuroprotective therapies and personalized treatment.

03

Conditions studied

  • Parkinson Disease

Keywords

  • Parkinson's disease
  • Exercise
  • Brain energetics
  • Positron Emission Tomography
  • MRI
  • PET
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Idiopathic PD according to UK Brain Bank criteria (modified to permit inclusion of subjects with a family history)
  2. Mild to moderate Parkinsonism (Hoehn \& Yahr stages I-III)
  3. Currently exercise less than 120 minutes per week (PD non-exercisers)

General exclusion criteria:

  1. atypical Parkinson syndrome (progressive supranuclear palsy, multiple system atrophy, drug-induced etc.);
  2. significant osteoporosis or arthritis;
  3. history of cancer within 5 years of study participation;
  4. high dose of radiation from other procedures within the year;
  5. not able to tolerate being off PD medication for up to 24 hours;
  6. a female subject who is breast-feeding or pregnant;
  7. current or past substance use problems;
  8. serious head injury with loss of consciousness for ≥ 5 minutes;
  9. people with other chronic diseases such as diabetes, kidney problems, high blood pressure, other known neurological disorders, or heart diseases;
  10. people who report having a significant respiratory disorder (e.g. asthma, (COPD)) or using home oxygen will be excluded to avoid discomfort or breathing difficulties from respiratory manipulations.
  11. current or past neurological disorder (e.g. strokes, seizures, neurodegenerative disease other than Parkinson's disease);
  12. current or past psychiatric disorders (e.g. depression, anxiety disorders);
  13. severe claustrophobia (a fear of closed in spaces);
  14. weight of more than 158kg (347 lbs);
  15. inability to lay still for up to 90 minutes;
  16. are not medically cleared to exercise;
  17. certain medications or conditions may impact participant's ability to participate and these will be discussed on a case by case basis with the participant and the study team.

MRI-specific exclusion criteria:

  1. Machinist or metalworkers;
  2. cardiac pacemakers, wires, or defibrillator;
  3. past injury where a piece of metal lodged in your eye or orbit;
  4. ferromagnetic aneurysm clip;
  5. artificial heart valve;
  6. electrical stimulator for nerves or bones;
  7. ear or eye implant;
  8. implanted drug infusion pump;
  9. coil, catheter, or filter in any blood vessel;
  10. orthopedic hardware (artificial joint, plate, screws);
  11. other metallic prostheses;
  12. shrapnel, bullets, or other metal fragments;
  13. dentures, braces, or retainer;
  14. surgery (brain or otherwise), tattoos, or injection into a joint in the last 6 weeks;
  15. pierced body parts (other than earrings) or tattooed eyeliner;
  16. non-MRI safe intrauterine device (IUD).

Subjects may be excluded following study enrollment if they meet any of the following exclusion criteria:

  1. significant cognitive impairment or depression;
  2. significant or unstable cardiovascular or respiratory disease - all subjects will undergo a screening aerobic exercise test;
  3. failure to comply with the exercise intervention program by not completing at least 60 of the 72 exercise classes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Immediate intervention start: active exercise

    Immediately starts the six month intervention of active exercise following the baseline scan.

    Other: Active exercise

  • Placebo comparator
    Delayed intervention start: passive exercise

    Starts the six month intervention of active exercise six months after the baseline scan. During the six month delay, participants in this arm undergo passive exercise.

    Other: Active exercise · Other: Passive exercise

Interventions

  • OtherActive exercise

    Thrice-weekly supervised intense aerobic exercise classes on cycle ergometers, in groups, for six months. Percentage of VO2 max will be used to regulate exercise intensity, based on an initial aerobic exercise test.

  • OtherPassive exercise

    Thrice-weekly supervised passive exercise classes consisting of stretching and/or yoga, in groups, for six months.

06

What researchers measure

Primary outcomes

  1. PET/MRI

    CMRO2 will be computed from MRI data and CMRGlu from PET data; their ratio will be used to assess brain energetics.

    Time frame: Six months

Other outcomes

  1. Clinical measure: motor function

    Motor function will be assessed using the MDS-Unified Parkinson's Disease Rating Scale (part III). The scale consists of 18 questions with each assigned a value in the range 0-4. Higher values indicate increasingly severe motor complications.

    Time frame: Six months

  2. Clinical measure: cognitive function

    Cognitive function will be assessed using the Montreal Cognitive Assessment. The assessment produces a score out of 30. Lower scores indicate increasingly impaired cognitive function.

    Time frame: Six months

07

Study locations

1 site
  • Pacific Parkinson's Research Centre
    Vancouver, British Columbia V6T 2B5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 71 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2020
First posted
Jun 11, 2020
StartActual
Jan 26, 2021
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04426786
Lead sponsor
Pacific Parkinson's Research Centre
Collaborators
Natural Sciences and Engineering Research Council, Canada
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Jan 26, 2021
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Sep 2, 2026

Study contacts

Vesna Sossi
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion